Nuvation Bio Inc. (NUVB)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. David T. Hung M.D. | Founder, President, CEO & Chairman | 1.2M | -- | 1958 |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer | 776.76k | -- | 1967 |
| Ms. Colleen Sjogren | Chief Commercial Officer | 615.84k | -- | 1971 |
| Mr. Philippe Pierre Sauvage | CFO & Principal Financial Officer | -- | -- | 1978 |
| Mr. Moses Makunje CPA | VP of Finance and Principal Accounting & Financial Officer | -- | -- | 1979 |
| Dr. Stephen Dang Ph.D. | Senior VP, General Counsel & Corporate Secretary | -- | -- | -- |
| Ms. Stacy Markel | Chief People Officer | -- | -- | 1965 |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer | 586.04k | -- | 1970 |
| Ms. Kerry A. Wentworth | Chief Regulatory Officer | -- | -- | 1973 |
| Dr. David Liu M.D., Ph.D. | Chief Medical Officer | 677.15k | -- | 1970 |
Nuvation Bio Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 273
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
August 4, 2025 at 12:30 PM UTC - August 8, 2025 at 12:30 PM UTC
Nuvation Bio Inc. Earnings Date